U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Guidance, Compliance, & Regulatory Information
  4. Drug Registration and Listing System (DRLS and eDRLS)
  5. Electronic Registration and Listing Compliance Program
  1. Drug Registration and Listing System (DRLS and eDRLS)

Electronic Registration and Listing Compliance Program

Establishment registration and drug listing data is submitted by drug manufacturers and own label drug distributors through electronic means using Structured Product Labeling format (SPL). Establishment registrations and drug listing data provide the agency with a list of all drug manufacturers currently manufacturing drugs for U.S. commercial distribution and a current inventory of all drugs in the U.S. commercial distribution. Part of this data is published online in the FDA National Drug Code Directory, FDA Label Repository, FDA Drug Establishment Current Registration Site and NIH’s DailyMed for public, health care professionals, and healthcare industry access.

Requirements for establishment registration and drug listing are outlined in section 510 of the Federal Food, Drug, and Cosmetic Act and part 207 of Title 21 of the Code of Federal Regulations (CFR), which was revised in 2016 and went into effect on November 29 of the same year.

Accuracy and integrity of establishment registration and drug listing data are essential to the FDA’s mission to minimize the exposure of the public to unsafe and ineffective drugs. Several key programs inside and outside the agency such as inspections and reimbursement rely upon registration and listing information. Although FDA has several automated validation rules in place to stop the submission of inaccurate and incomplete data at its entry point, many steps within the process cannot be automated.

Our compliance program focuses on ways to find inaccuracies in the data after it has been submitted to the agency. We subsequently take action to have firms correct those data inaccuracies and ultimately remove them from the public sites if corrections are not made as required. Certain violations of the FD&C Act can result in further actions such as a warning letter. To date, FDA has issued the following warning letters:

 Warning Letter/Company

 Issue Date

 Closeout Date

NuCare Pharmaceuticals 09/26/2019  
American Sales Company 7/11/2019  

Jessie Commodity Co., Ltd.


Close Out Letter

ABC Compounding Company Inc.


Close Out Letter

Netcos Co., Ltd.


Close Out Letter

United Exchange Corporation


Close Out Letter

AMI Cosmetic Co., Ltd.


Close Out Letter

Aphena Pharma Solutions-Tennessee, LLC



A-S Medication Solutions LLC.


Close Out Letter

Prestige Brands Holdings



Exact-Rx Inc



Targeted Medical Pharma, Inc. dba Physician Therapeutics



Wallace Cameron International Ltd



Pharmaceutical Associates Inc



RemedyRepack Inc.



Rebel Distributors Corp



Changzhou Qianhong Bio-Pharma Co., Ltd



Quzhou Chemsyn Pharm Co Ltd



Peking Medicine Manufactory



Korea Pharma Company Ltd



Zhejiang Xianju Chemical Pharmaceutical Factory



Changzhou Jialing Medicine Industry Co Ltd



If you have any questions about our registration and listing compliance program, or if you believe our published registration or listing data includes any error, please contact us at eDRLS@fda.hhs.gov.

Back to Top

Resources for You

Back to Top